High-risk prostate cancer: combination of high-dose, high-precision radiotherapy and androgen deprivation therapy
Bolla M, Verry C, Long JA. Curr Opin Urol. 2013 Jul;23(4):349-54. doi: 10.1097/MOU.0b013e328361ebfd.


aClinique Universitaire de Cancérologie-Radiothérapie bClinique Universitaire d'Urologie de Transplantation Rénale, Grenoble, France.



High-risk prostate cancer (PCa) harbours a risk of local, regional and systemic relapse requiring the combination of a loco-regional treatment such as external beam radiotherapy for controlling the pelvic-confined disease, combined with an androgen deprivation therapy (ADT) to potentiate irradiation and to destroy the infraclinical androgen-dependent disease outside the irradiated volume.


Many phase III randomized trials issued from the Radiation Therapy Oncology Group (USA) and from the EORTC Radiation Oncology Group have paved the way for establishing the indications of this combined approach.


For locally advanced PCa, the combination needs a long-term ADT (≥2 years) with luteinizing hormone-releasing hormone agonists. For high-risk localized PCa, the combination requires a 6-month complete androgen blockade. Image-guided intensity-modulated radiotherapy has replaced conventional irradiation and allows a dose escalation, improving the local control without increasing the toxicity. A multidisciplinary approach will enable physicians to tailor the treatment policy and a close cooperation with general practitioners and specialists will be set up to prevent as much as possible the side-effects of ADT.